The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients with MYC-expressing aggressive B cell non-Hodgkin lymphomas who fail two or more lines of therapy.
 
Daniel Jeffrey Landsburg
Consulting or Advisory Role - Curis
Research Funding - Curis; Curis (Inst); Takeda (Inst)
 
Sunita Nasta
Research Funding - Millennium
 
Jakub Svoboda
Consulting or Advisory Role - Seagen
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Pharmacyclics; Seagen
Travel, Accommodations, Expenses - Merck
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Celgene; Janssen; Prime Oncology; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); DTRM (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Regeneron (Inst); TG Therapeutics (Inst)
 
Stephen J. Schuster
Consulting or Advisory Role - Celgene; Gilead Sciences; Gilead Sciences; Merck; Nordic Nanovector; Novartis; Pharmacyclics
Research Funding - Adaptive Biotechnologies (Inst); Celgene (Inst); Gilead Sciences (Inst); Johnson & Johnson (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst)
 
Rachel L Sargent
No Relationships to Disclose